Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 55-61

  Decoster, L ^a   Schallier, D ^a   Everaert, H ^a   Nieboer, K ^a   Meysman, M ^a   Neyns, B ^a   De Mey, J ^a   De Greve J ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

18FDG PET; CT scan; Non small cell lung cancer; Prognosis; Response evaluation; Stage III unresectable; Survival

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 52149101615     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.015     Document Type: Article

References (21)

1. Pirozynski M. 100 years of lung cancer. Respir Med 100 (2006) 2073-2084
2. Lardinois D., Weder W., Hany T.F., Kamel E.M., Korom S., Seifert B., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Eng J Med 348 (2003) 2500-2507
3. 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors. Eur J Nucl Med Mol Imaging 34 (2007) 54-59
4. Molina J.R., Adjei A.A., and Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 130 (2006) 1211-1219
5. Pisters K.M., Kris M.G., Gralla R.J., Zaman M.B., Heelan R.T., and Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 11 (1993) 1757-1762
6. Weber W.A., and Wieder H. Monitoring chemotherapy and radiotherapy of solid tumours. Eur J Nucl Med Mol Imaging 33 (2006) S27-S37
7. 18F-FDG-PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47 (2006) 1059-1066
8. de Geus-Oei L.F., Van der Heijden H., Corstens F.H., and Oyen W.J. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. A systematic review. Cancer 110 (2007) 1654-1664
9. Patz E.F., Connolly J., and Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol 174 (2000) 769-774
10. MacManus M.P., Hicks R.J., Matthews J.P., McKenzie A., Rischin D., Salminen E.K., et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
11. Weber W.A., Petersen V., Schmidt B., Tyndale-Hines L., Link T., Peschel C., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 (2003) 2651-2657
12. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radiochemotherapy in stage III NSCLC. Eur J Nucl Med Mol Imaging 34 (2007) 463-471
13. Vansteenkiste J., Stroobants S.G., De Leyn P.R., Dupont P.J., and Verbeken E.K. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective pilot study. Ann Oncol 9 (1998) 1193-1198
14. Hoekstra C.J., Stroobants S.G., Smit E.F., Vansteenkiste J., van Tinteren H., Postmus P.E., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin oncol 23 (2005) 8362-8370
15. Schallier D., Neyns B., Fontaine C., Vande Steene J., De Mey J., Meysman M., et al. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non-small cell lung cancer. Lung Cancer 56 2 (2007) 247-254
16. World Health Organisation. A handbook for reporting results of cancer treatment: World Health Organisation 38 (1979), WHO Publication, Geneva, Switzerland
17. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 487-581
18. Peto R., and Peto J. Asymptotically efficient rank invariant procedures. J Roy Stat Soc A 135 (1972) 185-207
19. Cox D.R. Regression models and life tables. JR Stat Soc (B) 34 (1972) 187-220
20. Mikhaeel G. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 33 (2006) S22-S26
21. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 35 (2005) 186-196